Star Combo Pharma Limited (S66) Fair Value & Analysis
Consumer Defensive · AU · Market cap A$17.6M
Fair value as of: Jul 13, 2026
From 21 valuation models · updated 29 days ago
A strong business, screening 177% undervalued on our models.
What matters now
- The rarer combination: high quality (77/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case (A$0.2800). The market is more pessimistic than our downside scenario.
- The model range is unusually wide (A$0.2800 to A$0.9100). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 13, 2026.
How to read this chart
60‑month range A$0.0865 – A$0.3604 · fair‑value band A$0.2800 – A$0.9100 · the A$0.1300 price screens below the A$0.3600 fair value. Dashed = 300-day average. As of Jul 13, 2026.
Analysis
Star Combo Pharma Limited (S66) currently trades at A$0.1300, while our model-based Fair Value estimate is A$0.3600, implying the stock looks roughly 176.9% undervalued today. The Quality Score stands at 77/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Star Combo Pharma Limited generated revenue of A$24.0M at a net margin of 22.4%. Revenue declined 24.2% year over year. It earns a return on equity of 14.9%. The stock trades on a trailing P/E of 3.9. Fundamentals as of Jul 13, 2026
Our scenario range runs from A$0.2800 (bear case) to A$0.9100 (bull case); at A$0.1300, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 53% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -26% fair-value upside, at 177%, S66 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 21 models by family
Widest divergence: DCF Models (A$0.7300) versus Asset-Based (A$0.1900). Highest evidence: Growth DCF (80).
Notify me when S66 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 75 · Market factors (momentum, volatility) 17
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Star Combo Pharma Limited manufactures and distributes health food products and nutritional supplements in Australia and China. It operates in two segments, OEM and Retail. The company develops, manufactures, markets, and sells natural health supplements and skin care products.
Full company description
Star Combo Pharma Limited manufactures and distributes health food products and nutritional supplements in Australia and China. It operates in two segments, OEM and Retail. The company develops, manufactures, markets, and sells natural health supplements and skin care products. It also provides its products through e-commerce platform to Chinese health product consumers. The company sells its products under the Costar, Living Healthy, Amax, and J&K brands. Star Combo Pharma Limited was founded in 2004 and is based in Smithfield, Australia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Star Combo Pharma Limited reported revenue of A$27.8M in FY2025 versus A$26.7M in FY2021, a compound +1.0%/yr. Reported net income was A$5.2M in FY2025.
Watch S66: get an alert when its fair value changes →
Peer Group
Household & Personal Products · 244 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Household & Personal Products median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Jul 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Procter & Gamble Company PG | $146.80 | $108.16 | -26% |
| Unilever PLC ULN | 1,080 MXN | 1,273 MXN | +18% |
| Hindustan Unilever Limited HINDUNILVR | ₹2,144 | ₹1,000 | -53% |
| Essity AB ESSITYA | kr 279.00 | kr 250.02 | -10% |
| Godrej Consumer Products Limited GODREJCP | ₹1,088 | ₹367.64 | -66% |
| Marico Limited MARICO | ₹846.75 | ₹233.05 | -72% |
| APR Co 278470 | 375,000 KRW | 151,222 KRW | -60% |
| Dabur India Limited DABUR | ₹429.45 | ₹181.60 | -58% |
| Kimberly-Clark de México, S. A. B. de C. V., KIMBERA | 38.07 MXN | 50.09 MXN | +32% |
| PT Unilever Indonesia Tbk UNVR | 1,730 IDR | 1,934 IDR | +12% |
Compare Star Combo Pharma Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Star Combo Pharma Limited (S66) overvalued or undervalued?
What is the fair value of S66?
What is the quality score of S66?
What is the revenue of Star Combo Pharma Limited (S66)?
What is the net profit margin of S66?
Does Star Combo Pharma Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Star Combo Pharma Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.